A Phase 2 interventional study of GS-9131 and BIC in HIV-1-infection, sponsored by Gilead Sciences. Terminated at 2 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-05.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the short-term antiviral potency of GS-9131 functional monotherapy compared to placebo-to-match (PTM) GS-9131, each administered once daily with the existing failing antiretroviral (ARV) regimen as demonstrated by the proportion of participants achieving human immunodeficiency virus ribonucleic acid (HIV-1 RNA) > 0.5 log10 decreases from baseline after up to 14 days of therapy in HIV-1 positive, ARV treatment experienced adult participants with nucleos(t)ide resistant virus.
This is a two-part study. Part 1 consists of three cohorts: 2 Sentinel Cohorts and 1 Randomized Cohort. Eligible participants from Part 1 will proceed to Part 2 followed by an optional open-label extension.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment experienced participants will receive GS-9131 60 mg in addition to their current failing ARV regimen for a period of 10 days.
Drug: GS-9131 · Drug: ARV regimen
Treatment experienced participants will receive GS-9131 180 mg in addition to their current failing ARV regimen for a period of 14 days.
Drug: GS-9131 · Drug: ARV regimen
Participants will be randomized in 1:1:1:1 so as to receive GS-9131 in 3 active dose levels up to a maximum of 180 mg or Placebo to match GS-9131 in addition to their current failing ARV regimen for a period of 14 days in Part 1.
Drug: GS-9131 · Drug: ARV regimen
Participants who complete dosing in Sentinel Cohort 1 of Part 1 and show a reduction in plasma HIV RNA \> 0.5 log10 from their pre-GS-9131 baseline value at Day 11 and discontinue their current failing regimen will receive an optimized regimen consisting of GS-9131 60 mg + bictegravir (BIC) 30 mg + darunavir (DRV) 800 mg + ritonavir (RTV) 100 mg for a period of 24 weeks. After Week 24, participants will be given the option to participate in an open label extension and receive GS-9131 60 mg + BIC 75 mg + tenofovir alafenamide (TAF) 25 mg, for an additional 24 weeks or until Gilead Sciences elects to discontinue the study drug in that country, whichever occurs first.
Drug: GS-9131 · Drug: BIC · Drug: DRV · Drug: RTV
Participants who complete dosing in Sentinel Cohort 2 of Part 1 and show a reduction in plasma HIV RNA \> 0.5 log10 from their pre-GS-9131 baseline value at Day 15 and discontinue their current failing regimen will receive an optimized regimen consisting of GS-9131 180 mg + BIC 75 mg + TAF 25 mg, for a period of 24 weeks. After Week 24, participants will be given the option to participate in an open label extension and receive GS-9131 180 mg + BIC 75 mg + TAF 25 mg, for an additional 24 weeks or until Gilead Sciences elects to discontinue the study drug in that country, whichever occurs first.
Drug: GS-9131 · Drug: BIC · Drug: TAF
Tablet(s) administered orally once daily
Tablet(s) administered orally once daily
Tablet(s) administered orally once daily
Also known as: Vemlidy®
ARV regimen may consist of the ARV agents containing nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitor (NNRTI)
Tablet(s) administered orally once daily
Also known as: Prezista®
Tablet(s) administered orally once daily
Also known as: Norvir®
Part 1 Randomized Cohort: Percentage of Participants With Plasma HIV-1 RNA Decreases From Baseline Exceeding 0.5 log10 at Day 15
The criteria for analyzing percentage of participants with plasma HIV-1 RNA \> 0.5 log10 decrease from baseline in randomized cohort was at least 50% of the participants should achieve HIV-1 RNA \> 0.5 log10 decrease from baseline in the Part 1 sentinel cohort 2.
Time frame: Day 15
Part 1 Sentinel Cohort 1: Change From Baseline in Plasma log10 HIV-1 RNA at Day 11
Time frame: Baseline, Day 11
Part 1 Sentinel Cohort 2: Change From Baseline in Plasma log10 HIV-1 RNA at Day 15
Time frame: Baseline, Day 15
Part 1 Randomized Cohort: Change From Baseline in Plasma log10 HIV-1 RNA at Day 15
Time frame: Baseline, Day 15
Part 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Analysis at Week 24
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 24
Part 2: Change From Baseline in Plasma log10 HIV-1 RNA at Week 24
Time frame: Baseline, Week 24
Part 2: Change From Baseline in CD4+ Cell Count at Week 24
Time frame: Baseline, Week 24
Part 2: Number of Participants With Treatment Emergent Nucleos(t)Ide Reverse Transcriptase Inhibitor (NRTI) Mutations at the Time of Virologic Failure
Treatment emergent virological failure was defined as an event with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of the study drug. Virologic failure was defined as virologic rebound or as suboptimal virologic response in relation to pre-GS-9131 baseline plasma HIV-1 RNA levels. Virological rebound was defined as if participant at any visit after achieving HIV-1 RNA \< 50 copies/mL, a rebound in HIV-1 RNA ≥ 50 copies/mL, or a \>1 log10 increase in HIV-1 RNA from the nadir which was subsequently confirmed at the following scheduled or unscheduled visit. Suboptimal virologic response was defined as plasma HIV-1 RNA ≥ 200 copies/mL and reduction in HIV-1 RNA ≤ 1 log10 from pre-GS-9131 baseline at the Week 8 visit with confirmation at the next scheduled or unscheduled visit.
Time frame: From first dose up to Week 24
Part 2: Number of Participants With Treatment Emergent Protease Inhibitor (PI) Mutations at the Time of Virologic Failure
Treatment emergent virological failure was defined as an event with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of the study drug. Virologic failure was defined as virologic rebound or as suboptimal virologic response in relation to pre-GS-9131 baseline plasma HIV-1 RNA levels. Virological rebound was defined as if participant at any visit after achieving HIV-1 RNA \< 50 copies/mL, a rebound in HIV-1 RNA ≥ 50 copies/mL, or a \>1 log10 increase in HIV-1 RNA from the nadir which was subsequently confirmed at the following scheduled or unscheduled visit. Suboptimal virologic response was defined as plasma HIV-1 RNA ≥ 200 copies/mL and reduction in HIV-1 RNA ≤ 1 log10 from pre-GS-9131 baseline at the Week 8 visit with confirmation at the next scheduled or unscheduled visit.
Time frame: From first dose up to Week 24
Part 2: Number of Participants With Treatment Emergent Integrase Strand Transfer Inhibitor (INSTI) Mutations at the Time of Virologic Failure
Treatment emergent virological failure was defined as an event with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of the study drug. Virologic failure was defined as virologic rebound or as suboptimal virologic response in relation to pre-GS-9131 baseline plasma HIV-1 RNA levels. Virological rebound was defined as if participant at any visit after achieving HIV-1 RNA \< 50 copies/mL, a rebound in HIV-1 RNA ≥ 50 copies/mL, or a \>1 log10 increase in HIV-1 RNA from the nadir which was subsequently confirmed at the following scheduled or unscheduled visit. Suboptimal virologic response was defined as plasma HIV-1 RNA ≥ 200 copies/mL and reduction in HIV-1 RNA ≤ 1 log10 from pre-GS-9131 baseline at the Week 8 visit with confirmation at the next scheduled or unscheduled visit.
Time frame: From first dose up to Week 24
Participants were enrolled at study sites in Uganda and Zimbawe. The first participant was screened on 03 April 2018. The last study visit occurred on 09 December 2019.
| Milestone | Part 1 Sentinel Cohort 1: GS-9131 60 mg | Part 1 Sentinel Cohort 2: GS-9131 180 mg | Part 2 Sentinel Cohort 1: GS-9131 + BIC + DRV + RTV | Part 2 Sentinel Cohort 2: GS-9131 + BIC + TAF |
|---|---|---|---|---|
| Started | 11 | 10 | 0 | 0 |
| Completed | 11 | 10 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Part 1 Sentinel Cohort 1: GS-9131 60 mg | Part 1 Sentinel Cohort 2: GS-9131 180 mg | Part 2 Sentinel Cohort 1: GS-9131 + BIC + DRV + RTV | Part 2 Sentinel Cohort 2: GS-9131 + BIC + TAF |
|---|---|---|---|---|
| Started | 0 | 0 | 1 | 3 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 1 | 3 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 1 | 2 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 |
The criteria for analyzing percentage of participants with plasma HIV-1 RNA \> 0.5 log10 decrease from baseline in randomized cohort was at least 50% of the participants should achieve HIV-1 RNA \> 0.5 log10 decrease from baseline in the Part 1 sentinel cohort 2.
No measurements were reported for this outcome.
| log10 copies/mL | Sentinel Cohort 1: GS-9131 60 mg |
|---|---|
| Part 1 Sentinel Cohort 1: Change From Baseline in Plasma log10 HIV-1 RNA at Day 11 | -0.13 ± 0.268 |
| log10 copies/mL | Sentinel Cohort 2: GS-9131 180 mg |
|---|---|
| Part 1 Sentinel Cohort 2: Change From Baseline in Plasma log10 HIV-1 RNA at Day 15 | -0.29 ± 0.207 |
No measurements were reported for this outcome.
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Treatment emergent virological failure was defined as an event with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of the study drug. Virologic failure was defined as virologic rebound or as suboptimal virologic response in relation to pre-GS-9131 baseline plasma HIV-1 RNA levels. Virological rebound was defined as if participant at any visit after achieving HIV-1 RNA \< 50 copies/mL, a rebound in HIV-1 RNA ≥ 50 copies/mL, or a \>1 log10 increase in HIV-1 RNA from the nadir which was subsequently confirmed at the following scheduled or unscheduled visit. Suboptimal virologic response was defined as plasma HIV-1 RNA ≥ 200 copies/mL and reduction in HIV-1 RNA ≤ 1 log10 from pre-GS-9131 baseline at the Week 8 visit with confirmation at the next scheduled or unscheduled visit.
No measurements were reported for this outcome.
Treatment emergent virological failure was defined as an event with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of the study drug. Virologic failure was defined as virologic rebound or as suboptimal virologic response in relation to pre-GS-9131 baseline plasma HIV-1 RNA levels. Virological rebound was defined as if participant at any visit after achieving HIV-1 RNA \< 50 copies/mL, a rebound in HIV-1 RNA ≥ 50 copies/mL, or a \>1 log10 increase in HIV-1 RNA from the nadir which was subsequently confirmed at the following scheduled or unscheduled visit. Suboptimal virologic response was defined as plasma HIV-1 RNA ≥ 200 copies/mL and reduction in HIV-1 RNA ≤ 1 log10 from pre-GS-9131 baseline at the Week 8 visit with confirmation at the next scheduled or unscheduled visit.
No measurements were reported for this outcome.
Treatment emergent virological failure was defined as an event with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of the study drug. Virologic failure was defined as virologic rebound or as suboptimal virologic response in relation to pre-GS-9131 baseline plasma HIV-1 RNA levels. Virological rebound was defined as if participant at any visit after achieving HIV-1 RNA \< 50 copies/mL, a rebound in HIV-1 RNA ≥ 50 copies/mL, or a \>1 log10 increase in HIV-1 RNA from the nadir which was subsequently confirmed at the following scheduled or unscheduled visit. Suboptimal virologic response was defined as plasma HIV-1 RNA ≥ 200 copies/mL and reduction in HIV-1 RNA ≤ 1 log10 from pre-GS-9131 baseline at the Week 8 visit with confirmation at the next scheduled or unscheduled visit.
No measurements were reported for this outcome.
Collected over From first dose date up to 30 days after last study drug for Part 1 (Maximum: 44 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 Setinel Cohort 1: GS-9131 60 mg | 0/11 (0%) | 0/11 (0%) | 5/11 (45.5%) |
| Part 1 Sentinel Cohort 2: GS-9131 180 mg | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Event | Part 1 Setinel Cohort 1: GS-9131 60 mg | Part 1 Sentinel Cohort 2: GS-9131 180 mg |
|---|---|---|
| HypersomniaNervous system disorders | 0/11 | 4/10 |
| Urinary tract infectionInfections and infestations | 1/11 | 3/10 |
| Increased appetiteMetabolism and nutrition disorders | 0/11 | 3/10 |
| DizzinessNervous system disorders | 0/11 | 3/10 |
| DiarrhoeaGastrointestinal disorders | 0/11 | 2/10 |
| NauseaGastrointestinal disorders | 0/11 | 2/10 |
| VomitingGastrointestinal disorders | 0/11 | 2/10 |
| HeadacheNervous system disorders | 1/11 | 2/10 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/11 | 2/10 |
| AnaemiaBlood and lymphatic system disorders | 1/11 | 1/10 |
The Safety Analysis Set included all participants who took at least 1 dose of study medication.
| Age, Continuous(years) | Sentinel Cohort 1: GS-9131 60 mg | Sentinel Cohort 2: GS-9131 180 mg | Total |
|---|---|---|---|
| Mean | 38 ± 10.7 | 37 ± 6.6 | 38 ± 8.8 |
| Sex: Female, Male(Participants) | Sentinel Cohort 1: GS-9131 60 mg | Sentinel Cohort 2: GS-9131 180 mg | Total |
|---|---|---|---|
| Female | 11 | 10 | 21 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Sentinel Cohort 1: GS-9131 60 mg | Sentinel Cohort 2: GS-9131 180 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 11 | 10 | 21 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Sentinel Cohort 1: GS-9131 60 mg | Sentinel Cohort 2: GS-9131 180 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 11 | 10 | 21 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Sentinel Cohort 1: GS-9131 60 mg | Sentinel Cohort 2: GS-9131 180 mg | Total |
|---|---|---|---|
| Uganda | 11 | 5 | 16 |
| Zimbabwe | 0 | 5 | 5 |
| HIV-1 RNA(log10 copies/mL) | Sentinel Cohort 1: GS-9131 60 mg | Sentinel Cohort 2: GS-9131 180 mg | Total |
|---|---|---|---|
| Mean | 4.77 ± 0.703 | 4.46 ± 0.584 | 4.62 ± 0.652 |
| HIV-1 RNA Category(Participants) | Sentinel Cohort 1: GS-9131 60 mg | Sentinel Cohort 2: GS-9131 180 mg | Total |
|---|---|---|---|
| < 50 copies/mL | 0 | 0 | 0 |
| ≥ 50 copies/mL | 11 | 10 | 21 |
| CD4 Cell Count(cells/µL) | Sentinel Cohort 1: GS-9131 60 mg | Sentinel Cohort 2: GS-9131 180 mg | Total |
|---|---|---|---|
| Mean | 172 ± 164.1 | 289 ± 140.4 | 228 ± 161.0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2018 to primary completion in Dec 2019, 20 months.
Results were first posted in Jan 2021, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.